Britain and America have secured a important commercial pact that will preserve zero levies on British pharmaceutical shipments being sold in the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has agreed to increase spending on medicines through the National Health Service (NHS). This pledge secures that tariffs on these crucial exports will stay at zero for a duration of 36 months.
This development is in response to recent threats to significantly raise duties on patented drug products, with potential rates discussed reaching double the cost.
"This arrangement between the United Kingdom bolsters the worldwide climate for new treatments and brings much-needed equity to U.S.–U.K. pharmaceutical trade," an announcement noted.
Commercial Significance
Drugs constitute one of the the United Kingdom's largest exports to the US, which is easily the primary market for major UK drugmakers.
Trade data show that in the one-year period leading up to the third quarter, the UK exported pharmaceutical products worth over eleven billion pounds to the US. This value accounted for nearly one-fifth of total UK exports in that timeframe.
"This deal safeguards jobs, increases capital expenditure and facilitates the UK to establish itself as a global hub for medical research," the Business and Trade Secretary stated.
Key British Pledges
The deal includes several notable commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it considers new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a target to double total public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum drug companies must pay back to the NHS to prevent overspending will be limited at fifteen percent. Previously, refunds exceeded twenty percent.
Industry Background
The pact comes amid a protracted dispute between the drug companies and the ministers over medicine costs and NHS adoption.
The disagreement were intensified by assertions that American patients were charged several times more for the equivalent treatments than people in the UK and Europe.
Recently, several major drug company projects in the UK have been delayed or scrapped, while major investments have been pledged toward projects in the United States.
The Science Minister publicly accepted that the NHS had to spend more on drugs, noting that its budget allocation on drugs had shrunk as a proportion of its total funding over the previous ten-year period.
